Hospital Genten

Vol.3 No.2 Apr.- jun. 1986 J Prapokklao Hosp Clln Med Educat Center I 19lrdoEio steroid uffv cyclophosphamide o:ru{rlru s tu o:radsiorn 6o 16ooirrfi otilvn r uc r ru qfr utd'fuomulo 1 nfil /1:o6n6$nr*r6'rsteroid \d iha daa nt u a af TniJ 6 n 6 h w a n t aut v iln n {t 0"u n G{rhuRR. 61u?14rR fi o rfi aociau 1 rd ruduorn 6,000/ ou.r,rl. fiHnrdolqrflu$!! FSGS fi a:rufidosiour"y"lophosphamidelufiqorfio renal insufficiency 6nriountl'i-nuruflu es,ooo/nu.ilil. 1uiufi r s rad'lornlfr'grufirnoar6n luiufi zo 16-tfrsr6nntmuro soo 2:1ut4lurilur?n 12-16 fl 6.:fi r :rulilldfusr cvciln./nn.drururn6erdaond'ururci:;eiurJn6 \d6o Iophosphamideqrrufrr-lu 10 rdaudlu?urnfiorfioof,.ror.lrjnfi naturalaluh ur:hrif'trl yt.u.killer activity r:rnn'lr t,ooo LU ufi.:orn1frnll:-n:*r aha n un nmn u L iutt.tul a* v iln n #t o\nli-$s ' 2a ) - ) u!, )tol4lRlUARlilO?UYl 20 [Oftl 15.9 LU S{rljltolilRqt",e; u A,Posterior Fracture Dislocation of{udrtathe Hipr$'o.rvro na nfi 6 n o r6ous'ia rur fi f,larilu:; 6'uwithFractures of the Femoral HeadrJn6 uanornfru{?lu.nuu'.JldyiT Rt?nona.3y{ui1Epstein HC, Wiss DA, Cozen L.uonlqfl rosqlo:sfi fizunrirlfr' natural hller activityClin Orthop 1985; 201:9-17.oor o { uoi*aun'jr6 ruXuInu 6udo rfru ooo rfi oo0i'rcuu? urfsrriiur il.u. lorrt:hl4rt :ufilei';uq rmnaqr7aerln n,nfi auil nn ufi nynrr tr Ir r'ria'ril't am v iln n {t olunryi 6'ar'[oi:'unr::-nr*radr.:nrairunrfnullouiforifnt'tfiu r:losnr:6{n:rqnlri'rdrfi ra nrun*.rriudo rfl ufar{rlLate Resistanc€ to Corticosteroids in NephroticSyndromelouuornyrionrlnnro6ou type V o1il Thompsonand Epstein classification ty{:1so:litlfrrdoriioSrivastava RN, Agarwal RK, Moudgil A, Bhuyan UN. ui rr rudo n y}^r n\oi'iu dum:', r, u"' nfr t* uny oi n v1 r1finoJ Pediatr 1986; 108:66-70tr eA o tr16'6nur{rhu nephrotic syndrome 61fi{rlrulrariilnc so-50 rrsrflur?nl 1s fl nu'irfi 14lufind'un: yendulrli'n'ld nr: i'on: yon1fr r{rfi nrutu za :*rlu.:o :\6'H nd n'jr R r: a-o nr y q Rtfrfrr fi nra ra fi.r d { nril riruf rfi t o.:nr q n rfi l n: runu rir u# r nrsu firn.li 6 {nr v q nriJul:n6nunv6ooio steroid 1u.nilfl101'd'o{il?CI bi'uir fi drui 6 atfn f fi u il rai o nr:eir Ci'on: :q nlfiXtooR 2 T'rs rn:r;aroruotsr'tri61rooslfi'nrrifiods r :r8 r{rfi fir urnliln r rurr ad nR: vo nbirfrrf4uiasfin u ru:tltttn; [ilrl1ooqlo 1 t1U rrafiofirjra rz:ru rflums Blln fio:Jnfi ilnnit{fiufdronXrnrvonfiu:nfirin (arnilsd$ovu€l 4:1u orufir3rurflu nephrotic syndrome head f r a gment) fi ft ria ri ldlun r: ri r ri r eYorYo a: l^r nA - qgvi q -6o r -a fl srounuo.lsionr:fnuroim steroid u'rl{ 0.8- rfi a 6'o n'i v o nlri'rrirfi lu: rt lrufl r'r I'i r nrr 11 rilr il'o t'cra, i a'.tt v o )& |13.s fl (ro6l +.s iJ) r{oR'r:o:?orfiotqn^{u'jrri|un: r q nlri'rdr fi 6 r usi u: n o y ld'ru nd rio u n.j rfo s nr so[tuu minimal change a:ru Mesangial proliferativerusifi 6n'jrnr:f,nurd'rui6or$n rifiuilIosnr:6.rn fiu1figlomerulonephritis (MesPGN) z:to $nu ruirfi ufi u.lorir.:r6ar ui onr: rirdrCl'o nruu fi{ (16'H o6Focal segmental glomerulosclerosis (FSGS) t :tu fou oy ae) un;trJa r il1r nfl :,il6.rH nnr:tf,er::lnr rni.r'I A lle Xfl ?110 R 1 :',lu to sD2 ouuotqr ufi o rfi onr:dasia steroid ro.:u'rn::qnfrutrfi rin'ld r,r,r:r:fi nrt6onlui{nnr:ufilflu FSGS 'l6'r4rnr:snrorfiolqo*ofi 2 d"ru?ua :rs,{i{n*.iilrntiJurluu minimal changes 14u'jlln :*rlurir m : u; tu {rJT afi $fi oar1r^rn rndoulu type vdnr: fi: :u s rr nr n r: 6o Err ruH nnr:fn :ldururf, s.rnorflu FSGS frnaruo 1o''t:Jdeiuuirflu cyclophosphamider v{r 1 v ry'd ? s ilr n n d lf a s ns s o o s rfi o nr r :rian rL^r n11 :ru dilru e'tluooufluo.:sionr:fnur zlu rf,arulunrsfifi.r3o,s rluf,rlu[ijut?n1-z fl 6n o :rsfiornlrndltiJuqtrd rduunorru fl.u.